DUBLIN--(BUSINESS WIRE)--The "Cell-based Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global cell-based assay market reached a value of US$ 17.7 Billion in 2020.
The market is currently being catalysed by a number of factors, this includes rising investments in research and development, adoption of high throughput screening methods, increasing prevalence of various chronic diseases, growth in drug discovery activities, and the various advantages that cell-based assays offer over alternative technologies. Looking forward, the publisher expects the market to exhibit strong growth during 2021-2026.
Cell-based assays refer to any experiment that use live cells. The basic techniques include a variety of assays that can be used for the purpose of measuring cell toxicity, proliferation, motility as well as production of a particular cellular product and cellular morphology.
Cell-based assays provide a closer representation of the real life model since it employs live cells during experimentation. Cell-based assays have grown to become a versatile tool in healthcare research and development, particularly in the experiments which are designed to understand functionalities of specific cells like antibodies or drug efficacy on a group of cells.
There has been a significant increase in R&D funding by various public and private organisations so as to develop better and safer drugs. Moreover, technological advancements in cell-based assays have enabled researchers to start using this technology for drug discovery and toxicology studies.
Another major factor catalysing the growth of the market is the rising prevalence of lifestyle diseases such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, etc. which still have large unmet needs and have led to continuous investments in R&D. In addition, an increase in the adoption of the cell-based assay techniques for high throughput screening methods like toxicity studies, drug screening, in vitro testing, etc. are further driving this market.
- Based on the product and services, the market has been segmented as consumables, instruments, services and software. Currently, the consumables segment dominates the market, holding the largest share.
- Based on the technology, the market has been segmented as automated handling, flow cytometry, label-free-detection, high-throughput screening, and others.
- Based on the application, the market has been segmented as drug discovery, basic research, ADME studies, predictive toxicology and others. Currently, the drug discovery segment dominates the market, holding the largest share.
- On the basis of end-user, the market has been segmented as pharmaceutical and biotechnology companies; academic and government institutions; contract research organizations; and others.
- Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Amongst these, North America is the leading market, accounting for the majority of the market share.
Key Questions Answered in This Report:
- How has the global cell-based assay market performed so far and how will it perform in the coming years?
- What are the key regions in the global cell-based assay market?
- What has been the impact of COVID-19 on global cell-based assay market?
- What are the key product and service types in the global cell-based assay market?
- What are the major technologies in the global cell-based assay market?
- What are the major application segments in the global cell-based assay market?
- What are the key end-use segments in the global cell-based assay market?
- What are the various stages in the value chain of the global cell-based assay industry?
- What are the key driving factors and challenges in the global cell-based assay industry?
- What is the structure of the global cell-based assay industry and who are the key players?
- What is the degree of competition in the global cell-based assay industry?
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global Cell-Based Assay Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Product and Services
5.5 Market Breakup by Technology
5.6 Market Breakup by Application
5.7 Market Breakup by End-User
5.8 Market Breakup by Region
5.9 Market Forecast
5.10 SWOT Analysis
5.11 Value Chain Analysis
5.12 Porters Five Forces Analysis
6 Market Breakup by Product and Services
6.1.1 Reagents and Media
6.1.2 Cells and Cell Lines
6.1.3 Probes and Labels
6.2.2 Microplate Readers
6.2.3 High Throughput Screening
6.2.4 Liquid Handling Systems
7 Market Breakup by Technology
7.1 Automated Handling
7.2 Flow Cytometry
7.3 Label-Free Detection
7.4 High-Throughput Screening
8 Market Breakup by Application
8.1 Drug Discovery
8.2 Basic Research
8.3 ADME Studies
8.4 Predictive Toxicology
9 Market Breakup by End-User
9.1 Pharmaceutical and Biotechnology Companies
9.2 Academic and Government Institutions
9.3 Contract Research Organizations
10 Market Breakup by Region
11 Competitive Landscape
11.1 Market Structure
11.2 Key Players
11.3 Profiles of Key Players
- Becton Dickinson
- GE Healthcare Biopharma (Danaher Corporation)
- Thermo Fisher Scientific Inc.
- Merck Group
- Perkinelmer Inc.
- Charles River Laboratories Inc.
- Lonza Group Ltd.
- Cell Signaling Technology Inc.
- Promega Corporation
- Cell Biolabs Inc.
- Bio-Rad Laboratories Inc.
- Corning Inc
- F. Hoffmann-La Roche AG (Roche Holding AG)
For more information about this report visit https://www.researchandmarkets.com/r/1hz0ws